These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 17087656

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
    Holdenrieder S, Molina R, Gion M, Gressner A, Troalen F, Auge JM, Zancan M, Wycislo M, Stieber P.
    Clin Chem Lab Med; 2008; 46(5):588-99. PubMed ID: 18598201
    [Abstract] [Full Text] [Related]

  • 4. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125.
    Bayoumy S, Hyytiä H, Leivo J, Talha SM, Huhtinen K, Poutanen M, Hynninen J, Perheentupa A, Lamminmäki U, Gidwani K, Pettersson K.
    Commun Biol; 2020 Aug 21; 3(1):460. PubMed ID: 32826955
    [Abstract] [Full Text] [Related]

  • 5. Advances in the early detection of ovarian cancer: How to hear the whispers early.
    Cesario S.
    Nurs Womens Health; 2010 Jun 21; 14(3):222-34. PubMed ID: 20579298
    [No Abstract] [Full Text] [Related]

  • 6. Rapid, label-free, electrical whole blood bioassay based on nanobiosensor systems.
    Chang HK, Ishikawa FN, Zhang R, Datar R, Cote RJ, Thompson ME, Zhou C.
    ACS Nano; 2011 Dec 27; 5(12):9883-91. PubMed ID: 22066492
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Limitations to the use of the CA-125 antigen level in ovarian cancer.
    Markman M.
    Curr Oncol Rep; 2003 Jul 27; 5(4):263-4. PubMed ID: 12781066
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Soluble interleukin-2 receptors and CA 125 in ovarian cancer, a longitudinal and cross-sectional study.
    Burch D, Metcalfe S, Gallagher G, al-Azzawi F, Wheeler T.
    Eur J Gynaecol Oncol; 1994 Jul 27; 15(5):352-8. PubMed ID: 7828604
    [No Abstract] [Full Text] [Related]

  • 14. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
    Selman AE, Copeland LJ.
    Curr Oncol Rep; 1999 Sep 27; 1(1):71-6. PubMed ID: 11122801
    [Abstract] [Full Text] [Related]

  • 15. Elevated ovarian cancer marker (CA-125) in cirrhotic patients with intractable ascites.
    Zamir D, Jarchovsky J, Singer C, Weiner P.
    J Clin Gastroenterol; 1998 Sep 27; 27(2):154-5. PubMed ID: 9754780
    [No Abstract] [Full Text] [Related]

  • 16. Technical evaluation of the Beckman Coulter OV-Monitor (CA 125 antigen) immunoassay.
    Yagmur E, Driesch R, Gressner AM, Kiefer P.
    Clin Chem Lab Med; 2006 Sep 27; 44(4):420-2. PubMed ID: 16599835
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Is CA 125 actually a tumor marker for ovarian cancer?
    Collazos J.
    Acta Oncol; 1995 Sep 27; 34(2):268. PubMed ID: 7718270
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.